Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 781 to 790 of 1627 total matches.
Sofpironium (Sofdra) for Primary Axillary Hyperhidrosis
The Medical Letter on Drugs and Therapeutics • Aug 19, 2024 (Issue 1709)
retention (2%). ApplicationThe
Medical Letter ® Vol. 66 (1709) August 19, 2024
134
site reactions ...
The FDA has approved a 12.45% gel formulation of the
anticholinergic drug sofpironium (Sofdra – Botanix) for
treatment of primary axillary hyperhidrosis (excessive
underarm sweating) in patients ≥9 years old.
Med Lett Drugs Ther. 2024 Aug 19;66(1709):133-4 doi:10.58347/tml.2024.1709c | Show Introduction Hide Introduction
Aceclidine (Vizz) for Presbyopia
The Medical Letter on Drugs and Therapeutics • Nov 10, 2025 (Issue 1741)
on day 1, 3 hours after treatment.
The Medical Letter ® Vol. 67 (1741) November 10, 2025
178
Table 1 ...
The FDA has approved Vizz (Lenz Therapeutics), a
1.44% ophthalmic solution of the cholinergic agonist
aceclidine, for treatment of presbyopia in adults.
Aceclidine has been available in the EU for years for
treatment of open-angle glaucoma.
Med Lett Drugs Ther. 2025 Nov 10;67(1741):177-8 doi:10.58347/tml.2025.1741a | Show Introduction Hide Introduction
Garadacimab (Andembry) for Hereditary Angioedema Prophylaxis
The Medical Letter on Drugs and Therapeutics • Nov 10, 2025 (Issue 1741)
0.22 vs 2.07 attacks per month; relative
reduction 89% [95% CI 76%-95%]).7
The Medical Letter ® Vol ...
The FDA has approved garadacimab-gxii (Andembry –
CSL Behring), a subcutaneously injected inhibitor of
activated clotting factor XII, for prevention of hereditary
angioedema (HAE) attacks in patients ≥12 years old.
Garadacimab is the first activated factor XII inhibitor
to become available in the US for HAE prophylaxis
Med Lett Drugs Ther. 2025 Nov 10;67(1741):181-2 doi:10.58347/tml.2025.1741c | Show Introduction Hide Introduction
Etripamil Nasal Spray (Cardamyst) for Paroxysmal Supraventricular Tachycardia
The Medical Letter on Drugs and Therapeutics • Apr 13, 2026 (Issue 1752)
.
The Medical Letter ® Vol. 68 (1752) April 13, 2026
60
1. M Rehorn et al. Prevalence and incidence ...
The FDA has approved Cardamyst (Milestone), a
nasal spray formulation of the nondihydropyridine
calcium channel blocker etripamil, for conversion
of acute symptomatic episodes of paroxysmal
supraventricular tachycardia (PSVT) to sinus rhythm
in adults. Cardamyst is the first product containing
etripamil to be approved in the US. It is being marketed
as the only FDA-approved, self-administered, rapid-acting
treatment option for acute episodes of PSVT.
Med Lett Drugs Ther. 2026 Apr 13;68(1752):59-61 doi:10.58347/tml.2026.1752b | Show Introduction Hide Introduction
Breztri Aerosphere for Asthma
The Medical Letter on Drugs and Therapeutics • Jul 06, 2026 (Issue 1758)
. All rights reserved. ©2026. www.fdbhealth.com/drug-pricing-policy.
109
The Medical Letter ® Vol. 68 (1758 ...
Breztri Aerosphere (AstraZeneca), a three-drug inhaler
containing the inhaled corticosteroid (ICS) budesonide, the
long-acting antimuscarinic agent (LAMA) glycopyrrolate, and
the long-acting beta2-agonist (LABA) formoterol fumarate,
has been approved by the FDA for maintenance treatment
of asthma in patients ≥12 years old. It was approved in 2020
for treatment of chronic obstructive pulmonary disease
(COPD). Breztri Aerosphere is the second ICS/LAMA/LABA
combination to become available for treatment of asthma.
Trelegy Ellipta, which contains the ICS fluticasone, the...
Med Lett Drugs Ther. 2026 Jul 6;68(1758):108-9 doi:10.58347/tml.2026.1758c | Show Introduction Hide Introduction
Drugs for Thyroid Disorders
Treatment Guidelines from The Medical Letter • Aug 01, 2009 (Issue 84)
from The Medical Letter • Vol. 7 (Issue 84) August 2009
with 50-100 mcg/day, but others begin with full ...
Primary hypothyroidism is usually the result of Hashimoto's thyroiditis, thyroidectomy for hyperthyroidism, goiter or cancer, or radioactive iodine therapy for hyperthyroidism.
Drugs for HIV Infection
Treatment Guidelines from The Medical Letter • Feb 01, 2014 (Issue 138)
for HIV Infection
8 Treatment Guidelines from The Medical Letter • Vol. 12 (Issue 138) • February 2014 ...
Antiretroviral therapy is recommended for all HIV-infected
patients, both to reduce the risk of disease
progression and to prevent transmission of the virus to
others. Various guidelines for treatment of HIV infection
are available.
Antibacterial Drugs for Community-Acquired Pneumonia
The Medical Letter on Drugs and Therapeutics • Jan 25, 2021 (Issue 1616)
heart, lung, liver or renal
disease, diabetes, alcoholism, malignancy, or
11
The Medical Letter ® Vol ...
Treatment of community-acquired pneumonia (CAP)
is usually empiric, with selected antibiotic regimens
directed against some of the most common causative
pathogens. Recommended empiric regimens are
listed in Table 2; recommended antibiotic dosages for
treatment of CAP are listed in Tables 3 and 4. Joint
guidelines for treatment of CAP by the American
Thoracic Society and the Infectious Diseases Society of
America (ATS/IDSA) were updated in 2019.
Drugs for Hypothyroidism
The Medical Letter on Drugs and Therapeutics • Feb 20, 2023 (Issue 1670)
) ................... p 27
The Medical Letter ® Vol. 65 (1670) February 20, 2023
Thyroid Function Tests (TFTs ...
Primary hypothyroidism is usually the result of
Hashimoto's (autoimmune) thyroiditis, thyroidectomy,
or radioactive iodine therapy. Treatment of
hypothyroidism with replacement doses of thyroid
hormone is usually lifelong. Levothyroxine (LT4;
synthetic thyroxine; Synthroid, and others) is the drug
of choice.1
Med Lett Drugs Ther. 2023 Feb 20;65(1670):25-9 doi:10.58347/tml.2023.1670a | Show Introduction Hide Introduction
Acetaminophen Safety
The Medical Letter on Drugs and Therapeutics • Oct 28, 2002 (Issue 1142)
Letter, Inc. • 1000 Main Street, New Rochelle, NY 10801 • A Nonprofit Publication
Vol. 44 (W1142A ...
An FDA panel has recommended that stronger warnings about hepatotoxicity be added to the labeling for acetaminophen (www.fda.gov, search "acetaminophen hepatotoxicity").
